Evercore ISI Removes Krystal Biotech (KRYS) From Tactical Outperform List

Go back to Evercore ISI Removes Krystal Biotech (KRYS) From Tactical Outperform List

Krystal Biotech, Inc. (KRYS) Tops Q4 EPS by 59c

February 26, 2024 8:09 AM EST

Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q4 EPS of $0.30, $0.59 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $42.1 million versus the consensus estimate of $28.61 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.

... More